Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 years to evaluate long-term safety of this procedure. OBJECTIVES: To assess long-term safety of BT for 5 years. METHODS: Patients with asthma aged 18 to 65 years requiring high-dose inhaled corticosteroids (ICSs) (>750 μg/d of fluticasone propionate or equivalent) and long-acting β2-agonists (LABAs) (at least 100 μg/d of salmeterol or equivalent), with or without oral prednisone (≤30 mg/d), leukotriene modifiers, theophylline, or other asthma controller medications were enrolled in the Research in Severe Asthma (RISA) Trial. Patients had a prebronchodilator forced expiratory volume in 1 second of 50% or more of predicted, demonstrated methacholine airway hyperresponsiveness, had uncontrolled symptoms despite taking maintenance medication, abstained from smoking for 1 year or greater, and had a smoking history of less than 10 pack-years. RESULTS: Fourteen patients (of the 15 who received active treatment in the RISA Trial) participated in the long-term follow-up study for 5 years. The rate of respiratory adverse events (AEs per patient per year) was 1.4, 2.4, 1.7, and 2.4, respectively, in years 2 to 5 after BT. There was a decrease in hospitalizations and emergency department visits for respiratory symptoms in each of years 1, 2, 3, 4, and 5 compared with the year before BT treatment. Measures of lung function showed no deterioration for 5 years. CONCLUSION: Our findings suggest that BT is safe for 5 years after BT in patients with severe refractory asthma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00401986.

Original publication

DOI

10.1016/j.anai.2013.05.002

Type

Journal article

Journal

Ann Allergy Asthma Immunol

Publication Date

11/2013

Volume

111

Pages

402 - 407

Keywords

Adolescent, Adrenal Cortex Hormones, Adult, Aged, Albuterol, Androstadienes, Asthma, Bronchi, Bronchodilator Agents, Bronchoscopy, Catheter Ablation, Female, Fluticasone, Follow-Up Studies, Forced Expiratory Volume, Humans, Male, Methacholine Chloride, Middle Aged, Salmeterol Xinafoate, Young Adult